Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial
| Autor: | Tiffani K. Hamilton, Alice B. Gottlieb, Peter Compton, Craig L. Leonardi, Paul Kwon, Ivor Caro |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
Efalizumab Dermatology Placebo Antibodies Monoclonal Humanized law.invention Maintenance therapy Randomized controlled trial Psoriasis Area and Severity Index law Internal medicine Psoriasis Medicine Humans Immunologic Factors Glucocorticoids Intention-to-treat analysis business.industry Platelet Count Antibodies Monoclonal medicine.disease Combined Modality Therapy Surgery Clinical trial Treatment Outcome Fluocinolone Acetonide Ultraviolet Therapy business medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology. 54(4 Suppl 1) |
| ISSN: | 1097-6787 |
| Popis: | Background Efalizumab is a T cell–targeted therapy for psoriasis. Objective We sought to evaluate the efficacy and safety of long-term, continuous efalizumab therapy. Methods Of 339 patients enrolled in this ongoing, open-label, phase III study, after 3 months 290 qualified for and entered the maintenance treatment phase. Results Results for the first 27 months of this 36-month continuous therapy trial are available. At month 3, 41% of patients achieved at least a 75% reduction in Psoriasis Area and Severity Index (PASI) score; at month 27, 47% achieved at least a 75% reduction in PASI score (intent to treat, n=339). Among patients eligible for maintenance therapy (n = 290), 56% achieved at least a 75% reduction in PASI score at month 27. Moreover, the at least 90% reduction in PASI score rate increased through 18 months (33%). The safety profile with efalizumab was sustained throughout 27 months of continuous treatment with no new common events over time. Limitations Because the extended treatment period was not a randomized clinical trial, no formal comparative analyses versus placebo were conducted. Three-month placebo data from randomized, parallel, placebo-controlled studies are briefly discussed. Conclusions These results suggest that efalizumab maintains, and in some patients continues to improve, efficacy during long-term therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect